As the opioid crisis seethes, a long-lasting treatment could offer new ammunition

Launched this month, Brixadi from Braeburn gives patients a new tool to overcome addiction.

By Michael Gibney • Sept. 21, 2023

What happened to ivermectin?

The saga of the anti-parasitic drug continues.

By Alexandra Pecci • Sept. 20, 2023

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

The 2023 PharmaVoice 100

This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.

By Julia Himmel • Sept. 19, 2023

O.G. Ice-T teams up with Sanofi in horror-themed flu vax ad

The French pharma’s latest vaccine campaign aims to raise awareness about the flu’s complications for marginalized groups. 

By Karissa Waddick • Sept. 14, 2023

Catching up with 2022 PharmaVoice 100 honorees

Tapping into our growing community for expertise and inspiration.

By Meagan Parrish • Sept. 13, 2023

A healthcare paradox: Drugs are too expensive but ‘easy’ to afford, Americans say

A new poll shows that Americans generally support several key IRA provisions, including Medicare price negotiations.

By Alexandra Pecci • Sept. 12, 2023

Roz Brewer announces sudden departure as CEO of Walgreens

The exec who set out to overhaul the long-time pharmacy giant offered few details on why she's stepping down.

By Meagan Parrish • Sept. 1, 2023

A startup’s psychedelic delivery tech is grabbing attention. Will pharma listen?

Psycheceutical is developing a back-of-the-neck topical treatment for ketamine but believes the delivery route holds promise for far more drugs.

By Meagan Parrish • Sept. 1, 2023

Why pharma isn’t done tackling migraines

In the high-growth but competitive field of migraine treatments, CGRP drugs have changed the game — but the search is still on for more options. 

By Kelly Bilodeau • Aug. 28, 2023

Henrietta Lacks’ immortal cells put biopharma profits under a microscope

The HeLa cell line’s contributions to medical science were obtained without permission, and now biotechs profiting from its use are answering for it.

By Michael Gibney • Aug. 23, 2023

A rare disease researcher aims to tackle disability discrimination in new lawsuit

How a pediatric neurologist is advocating for herself and the disabled community in a legal battle with the Howard Hughes Medical Institute.

By Alexandra Pecci • Aug. 22, 2023

Leveraging data to drive efficiency and patient-centricity in clinical trials

Using real-time data, patient centricity and personalized medicine to accelerate clinical trials.

By Fareed Melhem, senior vice president and head of Medidata AI. Medidata is a Dassault Systèmes company. • Aug. 21, 2023

Woman of the Week: Novartis’ Christy Siegel

The oncology portfolio general manager for breast and women’s cancers, discusses the company’s recent “landmark” trial and how her family’s history connects her to patients.

By Taren Grom and Meagan Parrish • Aug. 15, 2023

Demand for weight loss drugs soars to nearly half of Americans

Drugs like the buzzy Ozempic are high on consumers’ radar — but lofty barriers to access remain.

By Alexandra Pecci • Aug. 15, 2023

Woman of the Week: AmyriAD Therapeutics’ Sharon Rogers

The CEO of the Alzheimer’s-focused biotech discusses its phase 3-ready candidate and what it could contribute to the bustling field.

By Taren Grom and Meagan Parrish • Aug. 9, 2023

Is the COVID-19 market crashing?

Pfizer’s recent earnings report could foretell major trouble in the market for pandemic products.

By Meagan Parrish • Aug. 3, 2023

As Barbie breaks the box office, women’s health investment explodes

Much like the year she first graced store shelves, Barbie has taken over the world. But now, the women's health landscape looks a whole lot different.

By Karissa Waddick • Aug. 2, 2023

With OTC birth control approved, access battles have just begun

Perrigo received the first FDA approval for an OTC birth control pill. Now, its global VP of women’s health says the company is working on the next challenge — affordability.  

By Karissa Waddick • July 26, 2023

Threads joins the social media fray. Here’s what it means for pharma marketers.

Meta’s new platform is drawing Twitter comparisons and could hold potential for pharma marketers in patient and HCP communication.

By Karissa Waddick • July 18, 2023

DCTs create fresh privacy challenges for review boards. Now there are guidelines.

A new toolkit developed by industry stakeholders paves the way for faster reviews.

By Kelly Bilodeau • July 17, 2023

The stories you’ve read the most in 2023 (so far)

From staff shortages to presidential candidates and the M&A outlook, here are our most-read stories from the first half of the year.

By PharmaVoice Staff • July 3, 2023

A unique study on COVID shows how machine learning can help personalize medicine

Based on real-world data from patients in China, researchers were able to pinpoint factors that led to recurring infections — and which drug combos helped.

By Kelly Bilodeau • June 26, 2023

Is America ready for a new kind of opioid?

Tris Pharma’s CEO is “betting the company” on a pain reliever with the power of an opioid and a lower chance of addiction. 

By Alexandra Pecci • June 12, 2023

First-party data: The answer to a cookie-less future

While online cookies revolutionized online advertising and are a big part of a $600 billion dollar industry, targeting consumer/patient behavior is about to get much more difficult

By Heather Campbell, VP Marketing, Adheris Health • June 12, 2023

Why cancer could be the ideal realm for psychedelic treatments

The CEO of Sunstone Therapies said the results of a recent trial testing psilocybin in cancer patients with depression were “remarkable.”

By Meagan Parrish • June 9, 2023